The Influences of Withdrawal and Daily Dose Reduction of Pioglitazone on Metabolic Parameters in Patients With Type 2 Diabetes: A Retrospective Longitudinal Observational Study
| Autor: | Hidekatsu Yanai, Sumie Moriyama, Akahito Sako, Hiroki Adachi, Hisayuki Katsuyama, Akiko Kawaguchi, Shuichi Mishima, Takayuki Fukunaga, Hidetaka Hamasaki |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Urology 030209 endocrinology & metabolism Type 2 diabetes Liver function Group B 03 medical and health sciences 0302 clinical medicine Internal medicine medicine In patient 030212 general & internal medicine Glycemic Pioglitazone business.industry General Medicine Body weight medicine.disease HDL-cholesterol Metformin Endocrinology Withdrawal Original Article Observational study business medicine.drug |
| Zdroj: | Journal of Clinical Medicine Research |
| ISSN: | 1918-3011 1918-3003 |
| DOI: | 10.14740/jocmr2611w |
| Popis: | Background: The aim of the study was to understand the influences of withdrawal or dose reduction of pioglitazone in patients with type 2 diabetes. Methods: We retrospectively picked up patients who had undergone withdrawal or daily dose reduction of pioglitazone after a continuous prescription for 3 months or longer between January 2010 and March 2014. We compared the data before the withdrawal or dose reduction of pioglitazone with the data at 3 or 6 months after those by a chart-based analysis. Results: Among 713 patients taking pioglitazone at least once during the studied period, 20 patients had undergone withdrawal of pioglitazone (group A) and 51 patients had undergone daily dose reduction (group B). The mean pioglitazone dose at baseline was 23 mg in subjects of group A, and 30 mg in group B. The number of subjects who had taken high-dose metformin (≥ 1,000 mg) and dipeptidyl peptidase-4 (DPP-4) inhibitors increased after the withdrawal or dose reduction of pioglitazone in both groups. Although no significant change was observed in plasma glucose and HbA1c levels, body weight significantly decreased at 3 and 6 months after the dose reduction in group B. The same tendency was observed in group A. Serum high-density lipoprotein-cholesterol (HDL-C) levels significantly decreased at 3 and 6 months after the withdrawal in group A. The serum alanine aminotransferase levels significantly increased 3 months after the withdrawal in group A. Conclusions: Present study demonstrated that the withdrawal of pioglitazone exacerbated serum HDL-C and liver function in patients with type 2 diabetes, although glycemic control could be maintained by using high-dose metformin or DPP-4 inhibitors. J Clin Med Res. 2016;8(8):585-590 doi: http://dx.doi.org/10.14740/jocmr2611w |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|